Prima BioMed (NASDAQ:IMMP) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Prima BioMed (NASDAQ:IMMP) from a sell rating to a hold rating in a report published on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Prima BioMed in a report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Prima BioMed has an average rating of “Sell”.

Prima BioMed Stock Down 1.0%

Shares of Prima BioMed stock opened at $2.95 on Friday. Prima BioMed has a 12-month low of $1.32 and a 12-month high of $3.53. The stock has a 50 day moving average price of $2.29 and a two-hundred day moving average price of $1.95.

Hedge Funds Weigh In On Prima BioMed

A hedge fund recently raised its stake in Prima BioMed stock. Jane Street Group LLC lifted its position in shares of Prima BioMed Ltd (NASDAQ:IMMP) by 14.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 51,574 shares of the biotechnology company’s stock after purchasing an additional 6,617 shares during the quarter. Jane Street Group LLC’s holdings in Prima BioMed were worth $91,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 2.32% of the company’s stock.

Prima BioMed Company Profile

Prima BioMed, trading as IMMP on NASDAQ, is a clinical-stage biotechnology company specializing in the development of immunotherapy products for cancer treatment. The company’s core technology platform centers on targeting the lymphocyte activation gene-3 (LAG-3), a checkpoint receptor that modulates T-cell activity. Prima BioMed’s lead candidate, eftilagimod alpha (IMP321), is a soluble LAG-3 protein designed to enhance antigen-presenting cell function and stimulate a tumor-specific immune response.